We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Bioxcel Therapeutics
18 own
15 watching
Current Price
$1.16
$-0.01
(-1%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
39.51M
52-Week High
10.58000
52-Week Low
1.03500
Average Volume
0.26M
Dividend Yield
--
P/E Ratio
--
Market Capitalization39.51M52-Week High10.5800052-Week Low1.03500Average Volume0.26MDividend Yield--P/E Ratio--What does the Bioxcel Therapeutics do?
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Read More
How much money does Bioxcel Therapeutics make?
News & Events about Bioxcel Therapeutics.
Business Wire
1 year ago
Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of BioXcel Therapeutics, Inc. (BioXcel or...
Business Wire
1 year ago
Law Offices of Howard G. Smith announces an investigation on behalf of BioXcel Therapeutics, Inc. (BioXcel or the Company) (NASDAQ: BTAI) investors concerning the Companys possible violations of...
Globe Newswire
1 year ago
SAN DIEGO, June 29, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether BioXcel Therapeutics (NASDAQ: BTAI), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose ...
PR Newswire
1 year ago
Thinking about buying stock in Lucid Group, Eos Energy Enterprises, Nio, DiaMedica Therapeutics, or BioXcel Therapeutics? Thinking about buying stock in Lucid Group, Eos Energy Enterprises, Nio, DiaMedica Therapeutics, or BioXcel Therapeutics? PR Newswire NEW YORK, June 29, 2023 NEW YORK, June 29...
Stock Options Channel
1 year ago
Investors eyeing a purchase of BioXcel Therapeutics Inc (BTAI) shares, but tentative about paying the going market price of 21.78/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February ...
Frequently Asked Questions
Frequently Asked Questions
What is Bioxcel Therapeutics share price today?
Can Indians buy Bioxcel Therapeutics shares?
How can I buy Bioxcel Therapeutics shares from India?
Can Fractional shares of Bioxcel Therapeutics be purchased?
What are the documents required to start investing in Bioxcel Therapeutics stocks?
What is today’s traded volume of Bioxcel Therapeutics?
What is today’s market capitalisation of Bioxcel Therapeutics?
What is the 52-Week High and Low Range of Bioxcel Therapeutics?
What percentage is Bioxcel Therapeutics down from its 52-Week High?
What percentage is Bioxcel Therapeutics up from its 52-Week Low?
Current Price
$1.16
$-0.01
(-1%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.